Development of a robust once-a-day glipizide matrix system

Area of Science:

• Pharmaceutical Technology
• Drug Delivery Systems
• Materials Science

Background:

• Modified-release formulations are crucial for optimizing drug efficacy and patient compliance.
• Hydroxypropylmethylcellulose (HPMC) is a widely used polymer for developing sustained-release drug delivery systems.
• Glipizide, a low-dose, pH-dependent drug, requires careful formulation to ensure consistent therapeutic outcomes.

Purpose of the Study:

• To evaluate the robustness of a new HPMC-based modified-release glipizide (10 mg) formulation.
• To assess the impact of compositional variations on the drug release profile.
• To determine the suitability of the formulation for scale-up operations.

Main Methods:

• Tablet formulations were prepared using dry blending and direct compression with varying HPMC concentrations.
• Dissolution testing was performed in a pH 6.8 buffer using standard paddle apparatus.
• Statistical analysis, including difference (f1) and similarity (f2) factors and ANOVA, was employed to compare release profiles.
• Particulate system characterization included Carr index, Hausner ratio, and rheological analysis.

Main Results:

• Dissolution profiles remained similar across formulations with +/-20% w/w compositional changes.
• Significant changes in drug dose (to half) did not alter the general release pattern.
• Drug release was primarily governed by the kinetics of hydration and erosion of the HPMC matrix.
• Particulate system characterization indicated reproducible release and potential for scale-up.

Conclusions:

• The developed HPMC-based glipizide matrix system exhibits high robustness to compositional changes.
• The formulation's release mechanism is predictable and consistent, relying on hydration and erosion kinetics.
• The system demonstrates potential for successful scale-up, adhering to regulatory guidelines for post-approval changes.